Hype to HIGH IMPACT: AI ImplEMEntation From Discovery to Delivery

23 - 25 September 2025 | Amsterdam

View 2025 Agenda

PARTNER WITH US

BOOK YOUR PLACE

Infographic | The EU AI Act Explained: What Every Pharma Leader Needs to Know

The EU AI Act is not just a compliance issue — it’s a strategic point for every pharma and healthcare leader using AI.

With enforcement beginning in 2026, the Act classifies most healthcare AI systems — from clinical decision support tools to AI-powered medical devices — as “high-risk”, triggering new and intensive requirements: transparency, data integrity, human oversight, and continuous monitoring.

Download this deep-dive analysis to understand:

What the EU AI Act really means for clinical trials, R&D, diagnostics, and digital health tools
How high-risk AI will be regulated and why most pharma use cases fall into this category
Why acting now creates a strategic edge, not just legal compliance

Now is the time to act. This guide breaks down what the EU AI Act means for your organisation, what will be required to comply, and how early preparation can turn regulatory pressure into a strategic advantage.

In Partnership With:

QUESTIONS?

Address: IQPC Ltd, 129 Wilton Road,
London SW1V 1JZ
Telephone: +44 (0) 1135 210 042
Fax: 44 (0) 207 368 9301
Email: enquire@iqpc.co.uk